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Alteration in the calcium metabolism in patients suffering from nephrotic syndrome is not uncommon. These include hypocalcemia, reduced serum vitamin 
D metabolites, elevated levels of immunoreactive Expansion 
parathormone (PTH), and normal serum phosphate levels [1-6]. 
Metabolic studies have demonstrated intestinal malabsorption 
of calcium [5] as well as excessive urinary losses of various 
vitamin D metabolites and their binding proteins [2,7] which, 
in turn, leads to decrease in bone mineral density [3,8] and put 
these patients at risk of osteomalacia of varying degree [9] as 
well as excessive bone resorption [10]. As glucocorticoids are 
the mainstay of treatment, they may further decrease the bone 
mineral density. Hence, early identification and management 
of these abnormalities, even before the decline of glomerular 
filtration rate (GFR), could ameliorate the growth retardation. 
However, there have been different schools of opinion 
regarding the incidence of hypocalcemia, hyperparathyroidism, 
osteomalacia, calcium, and vitamin D supplementation among 
the subgroups of nephrotic syndrome [11-14]. The present study 
was designed to study the calcium metabolism in different 
subgroups of nephrotic syndrome.
METHODS
This cross-sectional study was carried out on 30 children diagnosed 
with steroid sensitive nephrotic syndrome between the age of 1 
and 8 years, who presented to Pediatric Medicine Department at 
Pt. B. D. Sharma, PGIMS, Rohtak. The children were divided into 
three groups of 10 each as per the standard clinical definitions and 
criteria [15]. Group 1 comprises 10 patients who presented with the 
first episode or were infrequent relapser (IFR); Group 2 comprises 
10 patients who were FR or steroid-dependent nephrotic syndrome 
(FR/SDNS), and Group 3 comprises 10 patients in remission. 
Patients who had <2 relapses in the initial 6 months or <3 relapses 
in any 12-month period were categorized as IFR. Those presented 
with two or more relapses in initial 6 months or more than three 
relapses in any 12 months were categorized as FR. Patients who had 
two consecutive relapses while on alternate day steroids or within 
14 days of its discontinuation were categorized as SDNS. Patients 
who remain in remission for 6 months were taken as patients in 
remission. The following patients were excluded: (i) Chronic kidney 
disease, (ii) rickets, (iii) patients already on calcium supplementation, 
and (iv) patients with malabsorption syndrome.
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Background: Children with nephrotic syndrome are at risk of altered calcium metabolism because of the disease per se as well 
as steroid therapy even before fall in glomerular filtration rate (GFR). Objective: To compare the pattern of alteration in calcium 
metabolism in different subgroups (infrequent relapser [IFR], frequent relapser or steroid-dependent nephrotic syndrome [FR/
SDNS], and patients in remission) of nephrotic syndrome in children. Methods: We conducted a cross-sectional study in the 
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FR/SDNS (Group II), and patients in remission (Group III). Serum total calcium, ionized calcium, phosphate, parathormone (PTH), 
albumin levels, and urinary calcium and phosphate were measured, and X-rays of both lower limbs were done. Results: 10 patients 
in each group were compared. Serum total calcium, ionic calcium, and urinary calcium levels were decreased in patient with 
nephrotic syndrome during active disease. No difference was noted in serum phosphate, urinary phosphate, and GFR in all the 
three groups (p>0.05). Serum calcium and urinary calcium were significantly lower in Group II as compared to Group I (p<0.05), 
whereas serum PTH levels were significantly higher in Group II as compared to Group I (p<0.05). None of the patients with 
IFR and in remission had changes of osteopenia while 50% patients with FR/SDNS had features of osteopenia in their X-rays. 
Conclusion: Hypocalcemia is a common finding in children with nephritic syndrome. These children especially those with FR or 
SDNS should undergo careful monitoring of calcium, phosphorus, and PTH to prevent bone mineral disease.
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The study was approved by the Ethics Committee of the 
Institute. Following informed parental consent, all patients were 
evaluated including detailed history suggestive of nephrotic 
syndrome, history of similar episodes in the past, response to 
steroids, periods of remission, and cumulative dose of steroids 
used. The biometric data and the clinical findings were recorded 
for all the patients. The following laboratory investigations done: 
Hemoglobin, total and differential leukocyte count, and serum 
creatinine, calcium ionic calcium, and phosphorus, serum total 
protein, albumin, alkaline phosphatase, intact PTH level, urine 
examination, 24 h urinary protein, 24 h urinary calcium, and 
phosphorus. X-rays of both lower limbs were also done. GFR was 
calculated using the Schwartz formula. Serum ionic calcium levels 
were computed from the level of total serum calcium and total 
plasma proteins utilizing the McLean and Hastings Nomogram. 
Intact PTH levels were measured by chemiluminescence enzyme 
immunoassay. Investigations were done during relapse in Group I 
and Group II.
Statistical Analysis
Results were analyzed using STATA software version 11 
(College Station, TX, USA). Continuous data were expressed as 
mean±standard deviation and categorical variables as number (%). 
Results were analyzed for statistical significance using Student’s 
test for continuous variables and Chi-square test for discrete 
variables. The p<0.05 was considered statistically significant.
RESULTS
The present study was carried out on 30 children of nephrotic 
syndrome aged 1-8 years. 20 were male and 10 were female. 
Each group, i.e. IFR, FR/SDNS, and remission group comprised 
10 patients. The majority of children were of 3-6 years of age. The 
majority had up to 2 weeks duration of symptoms before reporting 
to the hospital. All patients who came in relapse received oral 
prednisolone; however, among patients with SDNS, two patients 
received levamisole and one patient received cyclophosphamide 
in addition to steroids. The baseline characteristics of the study 
population are shown in Table 1. Among 10 patients in Group I, 
five patients came with the first episode of nephrotic syndrome, 
four patients with first relapse, and one came with the second 
relapse. Among the 10 patients in Group II, two came with 
5th relapse, one with 6th, two with 7th, and one with 8th relapse and 
two each with 9th and 10th relapse.
The mean total serum calcium was 7.97±0.349 mg/dl in 
Group I, 7.40±0.664 mg/dl in Group II, and 8.84±0.544 mg/dl 
in Group III patients, respectively. Among subgroups, serum 
calcium levels were significantly lower in patients in Group II as 
compared to Group III (p<0.01) and Group I (p<0.05) (Table 2). 
In patients with active disease, serum ionic calcium was also 
found to be decreased. Serum ionic calcium levels in Group II 
(FR/SDNS) patients were significantly lower than Group I 
patients (p<0.01) and Group III patients (p<0.05). Similarly, 
ionic calcium in Group I patients were significantly lower than 
Group III patients (p<0.05) (Table 2).
As shown in Table 2, serum PTH levels were significantly 
higher in Group II (FR/SDNS) as compared to Group III 
(p<0.001) and Group I (p<0.05). Similar results were obtained 
while comparing Group I patients with Group III (p<0.001). 
Serum phosphate levels were found to be normal in all groups. No 
significant difference was noted in urinary phosphate levels and 
GFR between all groups (p>0.05). Serum proteins were found 
significantly higher in Group III than in Group I and Group II 
patients (p<0.001); however, no significant difference was noted 
between Group I and Group II (p>0.05). In our study, Group I and 
Group III patients had no changes of osteopenia; however, 5 out 
of 10 patients of Group II had radiological features of osteopenia 
in their X-rays.
DISCUSSION
This cross-sectional study revealed that hypocalcemia is a 
common finding in patients with nephrotic syndrome during 
active disease which is in accordance to previous studies [16-20] 
and in contradiction to studies which have reported normal 
calcium levels [2,21,22]. On subgroup analysis, serum calcium 
levels were found to be significantly lower in FR/SDNS patients 
as compared to IFR patients. This lower calcium levels may be due 
to longer courses of steroid in FR/SDNS and which, in turn, leads 
to decreased gastrointestinal calcium absorption and increased 
urinary calcium excretion by decreasing its reabsorption in the 
renal tubule, resulting in a negative calcium balance.
These results are also in accordance with a study by Gulati 
et al. [12], in which symptomatic hypocalcemia was observed in 
6 of 70 (8.6%) children with FR/SDNS as compared to compared 
with none of 30 children with IFR. Same study [12] also found 
corrected mean serum calcium level significantly lower in FR as 
compared with IFR. However, a recent study by Naglaa et al. [14] 
found no difference in serum calcium in two groups of nephrotic 
syndrome. We found normal serum calcium levels in the patients 
in remission, which is in accordance with the study by Huang 
et al. [18].
Earlier it was thought that hypocalcemia in nephrotic 
syndrome is due to the reduction in the protein bound calcium 
Table 1: Baseline characteristics of the patients
Baseline characteristics Group I
(N=10) (%)
Group II
(N=10) (%)
Group III
(N=10) (%)
Age (years)
1-3 3 (30) 1 (10) 1 (10)
3-6 5 (50) 7 (70) 7 (70)
6-8 2 (20) 2 (20) 2 (20)
Duration of symptoms
Up to 2 weeks 5 (50) 6 (60) -
2 weeks to 1 month 3 (30) 2 (20) -
1 month to 3 months 1 (10) 2 (20) -
3 months to 4 months 1 (10) - -
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fraction secondary to heavy proteinuria [23,24] and serum ionized 
fraction was not thought to be affected [25]. However, subsequent 
studies showed that the reduction in serum calcium concentration 
was not only in the protein bound fraction but also in ionized 
calcium [6,10,26-28]. These changes cannot be attributed to renal 
insufficiency because most nephrotic patients with this alteration 
showed normal or slightly reduced GFR [6,10,26-28]. Serum 
ionic calcium levels were found to be lower in patients during 
active disease than patients in remission which can be explained 
by frequent urinary losses of vitamin D metabolites and calcium 
during relapse [3,29].
In our study, ionic calcium levels were lower in FR/SDNS 
patients than IFR patients in contrast to the study by Nurmalia 
et al., where no differences were seen between these two 
groups [13]. 24 h urinary calcium was observed to be decreased 
during active disease, and it was significantly lower in FR/SDNS 
patients than IFR patients (p<0.05). Similar findings were found 
in other studies also [5,30]. Our study found normal serum 
phosphate levels in all the three groups, which are in accordance 
with previous studies [17,19,21,22,29,31,32]. However, in a 
study by Feinstein et al., serum phosphate levels were found to be 
elevated during relapse which normalized in remission in patients 
with SSNS [33].
The majority of the previous studies showed that despite 
low ionized serum calcium and histological evidence of 
secondary hyperparathyroidism in some patients, PTH levels 
were not consistently elevated in nephrotic syndrome (NS) 
patients [2,3,9,19,21,22]. On the other hand, some studies 
reported high PTH levels [1,18,29]. Our study also showed 
raised PTH levels during active disease and FR patients were 
found to have significantly higher PTH levels than IFR patients 
(p<0.05) that can be explained by the longer duration of disease 
and higher doses of steroids received by the FR children. This 
result is consistent with a recent study by Mohamed and Abdel-
Latif [11] but is in contrast to that reported by Gulati et al. [12]. 
Our study also showed similar results as shown by Freundlich 
et al. that biochemical abnormalities related to NS normalized 
during remission [29].
There have been discrepancies in studies regarding bone 
mineralization and steroid therapy in patients with nephrotic 
syndrome. In our study, patients with IFR/first episode and 
patients in remission had no changes of osteopenia in their 
X-rays. However, 50% of FR/SDNS patients had these changes. 
Similarly, Gulati et al. revealed the incidence of osteoporosis up to 
22% of patients with nephrotic syndrome, 28% of FRNS/SDNS/
SRNS, and 7% of IFR patients [12]. Greater dose and longer 
courses of steroids in these patients have been implicated as the 
reason behind this. Although some studies have related defective 
bone mineralization with dose of corticosteroids in children 
with NS [8,34-36], others found no difference in bone mineral 
content in children receiving corticosteroids compared with those 
who were off steroids [37]. Similar discrepancies are regarding 
the role of supplementation with calcium and vitamin D in these 
patients with some studies favoring supplementation [17,38,39] 
while others do not [40].
Limitations of our study include that we have not measured 
vitamin D levels and bone mineral density in these patients 
which is the new area of interest and could help us in learning 
the calcium metabolism in a better way. Second, sample size 
was small, and it was not calculated as we cater less number of 
patients with SDNS/FRNS. Furthermore, the dietary intake of 
calcium and duration of sun exposure was not taken into account 
in our study. Finally, we have not included patients with the 
steroid-resistant nephrotic syndrome. Our results suggest that 
children with the active nephrotic syndrome, especially those 
with FR/SDNS should undergo careful monitoring of calcium, 
25(OH)D, phosphorus, and PTH to prevent renal osteodystrophy, 
low turnover bone disease. However, studies with larger samples 
are still required to confirm these findings.
CONCLUSION
Changes in calcium levels in patients with nephrotic syndrome 
are considered to be due to urinary losses of these metabolites or 
their carrier proteins or secondary to corticosteroid therapy, but 
the exact biochemical basis for these changes remains speculative. 
Because of the potential adverse effects of calcium and vitamin D 
deficiency on the skeleton and other organ systems in these 
patients, especially growing children, widespread screening with 
serum calcium levels and supplementation of calcium should be 
considered.
Table 2: Comparison of biochemical parameters between patients of three groups
Biochemical parameters Group I Group II p valuea Group III p valueb p valuec
Serum calcium (mg/dl) 7.97±0.349 7.40±0.664 <0.05 8.84±0.544 <0.001 <0.01
Serum IONIC calcium 3.98±0.204 3.59±0.303 <0.01 4.25±0.246 <0.05 <0.05
Serum PO4 4.92±0.792 5.01±1.192 >0.05 5.09±1.683 >0.05 >0.05
Serum PTH 80.5±13.77 94.66±13.9 <0.05 28.1±23.3 <0.001 <0.001
Urinary calcium 4.61±2.00 2.83±1.52 <0.05 24.61±20.5 <0.01 <0.001
Urinary phosphate 1.00±0.646 1.01±0.402 >0.05 1.14±0.569 >0.05 >0.05
GFR 91.36±13.24 92.63±14.04 >0.05 96.91±28.10 >0.05 >0.05
Serum proteins 5.37±0.64 5.41±0.49 >0.05 6.43±0.54 <0.001 <0.001
aDifference between Group I and Group II, bDifference between Group I and Group III, cDifference between Group II and Group III. PTH: Parathormone, GFR: Glomerular 
filtration rate
Vol 3 | Issue 3 | Jul - Sep 2016 Indian J Child Health 219
Mehta and Nanda Calcium metabolism in nephrotic syndrome
REFERENCES
1. Goldstein DA, Haldimann B, Sherman D, Norman AW, Massry SG. 
Vitamin D metabolites and calcium metabolism in patients with 
nephrotic syndrome and normal renal function. J Clin Endocrinol Metab. 
1981;52(1):116-21.
2. Lambert PW, De Oreo PB, Fu IY, Kaetzel DM, von Ahn K, Hollis BW, 
et al. Urinary and plasma Vitamin D3 metabolites in the nephrotic syndrome. 
Metab Bone Dis Relat Res. 1982;4(1):7-15.
3. Freundlich M, Bourgoignie JJ, Zilleruelo G, Jacob AI, Canterbury JM, 
Strauss J. Bone modulating factors in nephrotic children with normal 
glomerular filtration rate. Pediatrics. 1985;76(2):280-5.
4. Alon U, Chan JC. Calcium and Vitamin D homeostasis in the nephrotic 
syndrome: Current status. Nephron. 1984;36(1):1-4.
5. Lim P, Jacob E, Tock EP, Pwee HS. Calcium and phosphorus metabolism in 
nephrotic syndrome. Q J Med. 1977;46(183):327-38.
6. Goldstein DA, Oda Y, Kurokawa K, Massry SG. Blood levels of 
25-hydroxyvitamin D in nephrotic syndrome. Studies in 26 patients. Ann 
Intern Med. 1977;87(6):664-7.
7. Schmidt-Gayk H, Grawunder C, Tschöpe W, Schmitt W, Ritz E, 
Pietsch V, et al. 25-hydroxy-Vitamin-D in nephrotic syndrome. Lancet. 
1977;2(8029):105-8.
8. Lettgen B, Jeken C, Reiners C. Influence of steroid medication on bone 
mineral density in children with nephrotic syndrome. Pediatr Nephrol. 
1994;8(6):667-70.
9. Tessitore N, Bonucci E, D’Angelo A, Lund B, Corgnati A, Lund B, et al. 
Bone histology and calcium metabolism in patients with nephrotic syndrome 
and normal or reduced renal function. Nephron. 1984;37(3):153-9.
10. Malluche HH, Goldstein DA, Massry SG. Osteomalacia and 
hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin 
Invest. 1979;63(3):494-500.
11. Mohamed GB, Abdel-Latif EA. Serum osteoprotegerin (OPG) in 
children with primary nephrotic syndrome. Saudi J Kidney Dis Transpl. 
2011;22(5):955-62.
12. Gulati S, Godbole M, Singh U, Gulati K, Srivastava A. Are children with 
idiopathic nephrotic syndrome at risk for metabolic bone disease? Am J 
Kidney Dis. 2003;41(6):1163-9.
13. Nurmalia LD, Tambunan T, Amir I. Comparisons of bone mineral density 
in steroid dependent, frequent relapse, and infrequent relapse nephrotic 
syndrome children. Paediatr Indones. 2010;50(4):193-8.
14. Boraey NF, Addosooki A, Mohammad MA, El-Sonbaty MM, El-Toukhy SE. 
Metabolic bone disease in children with idiopathic nephrotic syndrome. Life 
Sci J. 2012;9(4):275-80.
15. Bagga A. Revised guidelines for management of steroid-sensitive nephrotic 
syndrome. Indian J Nephrol. 2008;18(1):31-9.
16. Dasitania V, Chairulfatah A, Rachmadi D. Effect of calcium and Vitamin D 
supplementation on serum calcium level in children with idiopathic 
nephrotic syndrome. Paediatr Indones. 2014;54(3):163.
17. Lisa C, Julia M, Kusuma PA, Sadjimin T. Risk factors for low bone density 
in pediatric nephrotic syndrome. Paediatr Indones. 2011;51(2):61.
18. Huang JP, Bai KM, Wang BL. Vitamin D and calcium metabolism in 
children with nephrotic syndrome of normal renal function. Chin Med J 
(Engl). 1992;105(10):828-32.
19. Kosan C, Ayar G, Orbak Z. Effects of steroid treatment on bone mineral 
metabolism in children with glucocorticoid-sensitive nephrotic syndrome. 
West Indian Med J. 2012;61(6):627-30.
20. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, 
Kitch BT, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 
1998;338(12):777-83.
21. Mittal SK, Dash SC, Tiwari SC, Agarwal SK, Saxena S, Fishbane S. Bone 
histology in patients with nephrotic syndrome and normal renal function. 
Kidney Int. 1999;55(5):1912-9.
22. Panczyk-Tomaszewska M, Adamczuk D, Kisiel A, Skrzypczyk P, 
Przedlacki J, Górska E, et al. Markers of bone metabolism in children 
with nephrotic syndrome treated with corticosteroids. Adv Exp Med Biol. 
2015;840:21-8.
23. Rubin MI. Nephrotic Syndrome. In: Rubin MI, Barett TM, editors. Pediatric 
Nephrology. Baltimore: William and Wilkins; 1975. p. 454-98.
24. Diammond KN. The nephrotic syndrome. In: Vaughan VC, Behrman RE, 
editors. Nelson Textbook of Pediatrics. Philadelphia, PA: W.B Sanders; 
1987. p. 1332-30.
25. McEnery PT, Strife CF. Nephrotic syndrome in childhood. Management and 
treatment in patients with minimal change disease, mesangial proliferation, 
or focal glomerulosclerosis. Pediatr Clin North Am. 1982;29(4):875-94.
26. Haldimann B, Healy M, Jelliffe R, Goldstein DA, Pattabhiraman R, 
Massry SG. Effect of an oral dose of 25-hydroxyvitamin D3 on its blood 
levels in patients with the nephrotic syndrome. J Clin Endocrinol Metab. 
1980;50(3):470-4.
27. Freundlich M, Jacob AI, Canterburry JM, Zillerulo G. Gorman H, 
Bourgoignie JJ, et al. Altered mineral homeostasis in children with nephrotic 
syndrome and normal renal functions. Kidney Int. 1983;23:100.
28. Alon U, Chan JC. Calcium and Vitamin-D metabolism in nephrotic 
syndrome. Int J Pediatr Nephrol. 1983;4(2):115-8.
29. Freundlich M, Bourgoignie JJ, Zilleruelo G, Abitbol C, Canterbury JM, 
Strauss J. Calcium and Vitamin D metabolism in children with nephrotic 
syndrome. J Pediatr. 1986;108(3):383-7.
30. Scriver Wde M. Observations on the excretion of calcium in two cases of 
nephrosis treated with parathyroid extract. J Clin Invest. 1928;6(1):115-25.
31. Farrington K, Newman SP, Varghese Z, Moorhead JF. Dissociation between 
calcium and phosphate absorption in nephrotic syndrome. Clin Sci (Lond). 
1983;65(4):437-40.
32. Strickler GB, Burke EC. External calcium and phosphorus balances. 
A comparative study of renal disease and the celiac syndrome. Am J Dis 
Child. 1963;106:154-60.
33. Feinstein S, Becker-Cohen R, Rinat C, Frishberg Y. Hyperphosphatemia 
is prevalent among children with nephrotic syndrome and normal renal 
function. Pediatr Nephrol. 2006;21(10):1406-12.
34. Fujita T, Satomura A, Hidaka M, Ohsawa I, Endo M, Ohi H. Acute alteration 
in bone mineral density and biochemical markers for bone metabolism 
in nephrotic patients receiving high-dose glucocorticoid and one-cycle 
etidronate therapy. Calcif Tissue Int. 2000;66(3):195-9.
35. Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR. Increased 
osteoblastic activity and expression of receptor activator of NF-kappaB ligand 
in nonuremic nephrotic syndrome. J Am Soc Nephrol. 2005;16(7):2198-204.
36. Kyrieleis HA, Löwik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, 
et al. Long-term outcome of biopsy-proven, frequently relapsing 
minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 
2009;4(10):1593-600.
37. Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. 
Long-term, high-dose glucocorticoids and bone mineral content in 
childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med. 
2004;351(9):868-75.
38. Choudhary S, Agarwal I, Seshadri MS. Calcium and Vitamin D for 
osteoprotection in children with new-onset nephrotic syndrome treated with 
steroids: A prospective, randomized, controlled, interventional study. Pediatr 
Nephrol. 2014;29(6):1025-32.
39. Gulati S, Sharma RK, Gulati K, Singh U, Srivastava A. Longitudinal 
follow-up of bone mineral density in children with nephrotic syndrome and 
the role of calcium and Vitamin D supplements. Nephrol Dial Transplant. 
2005;20(8):1598-603.
40. Banerjee S, Basu S, Sengupta J. Vitamin D in nephrotic syndrome remission: 
A case-control study. Pediatr Nephrol. 2013;28(10):1983-9.
Funding: None; Conflict of Interest: None Stated.
How to cite this article: Mehta P, Nanda S. Comparison of calcium 
metabolism in different subgroups of nephrotic syndrome in children. Indian 
J Child Health. 2016; 3(3):216-219.
